No abstract available.
Danazol* ; Panniculitis*

No abstract available.
Danazol* ; Humans

BACKGROUND: Several modalities have been used for the treatment of livedo vasculitis. However, in some cases conspicious morbidity is caused by recurrent painful ulceration resistant to therapy. OBJECTIVE: This study was conducted to determine the effectiveness and adverse effects of the danazol in treatment of livedo vasculitis. METHODS: Nine patients with ulcerative lesions due to livedo vasculitis were included for danazol therapy. Danazol 200mg was administered daily for 4 to 8 weeks. RESULTS: Eight of the patients showed remarkable improvement and were satisfied with this therapy. Significant adverse effects were not observed. CONCLUSION: We suggest that a low dose of danazol may be considered as the first line of treatment and is worthwhile to try in cases recalcitrant to the other treatment.
Danazol* ; Humans ; Ulcer ; Vasculitis*

Extract of Panacrine is material of preparing Panacrin drug that inhibited tumor in cancer treatment. Study on standardization of extract of Panacrine was carried out in order to stabilize Panacrin production process. Qualitative criteria were humidity <10%, total ash <9%, total content of extract in ethanol 50% should be more than 80%, and extract should have positive reaction with saponin of Panax notoginseng Burk., alcaloid of Carica papaya L. and Crinum latifolium L
Danazol ; Therapeutics ; neoplasms ; Pharmaceutical Preparations ;

Livedoid vasculitis is characterized clinically by smooth or depressed ivory-white scars surrounded by hyperpigmentation and telangiectasia with or without preceding purpuric in-filtrated papules and plaques and histologically by intravascular deposition of fibrin. Its pathophysiology is still obscure. Many treatment modalities have been used, but results are not satisfactory. Recently, there have been experiences of successful treatments with danazol, a synthetic androgen. We used danazol in three patients who presented with livedoid vasculitis and were relatively resistant to treatments with aspirin and/or pentoxifylline. After 4 to 8 weeks, there was remarkable clinical improvement in all three patients.
Aspirin ; Cicatrix ; Danazol* ; Fibrin ; Humans ; Hyperpigmentation ; Pentoxifylline ; Telangiectasis ; Vasculitis*

Hereditary angioedema (HAE) is rare disorder due to C1-inhibitor deficiency (C1-INH) that are debilitating and may be life-threatening. HAE is a lack of consensus concerning diagnosis, therapy, and management, particularly in Vietnam. In this case report, we report a 40-year-old male patient with typical clinical symptoms and family history but he showed normal C4 level, and we could not measure C1q and C1-INH level. However, the diagnosis of HAE can be made based on typical clinical symptoms and the favorable prophylactic response to danazol treatment. Based on these findings, we suggest that he has type I HAE, although he showed normal C4 level.
Adult ; Angioedemas, Hereditary ; Consensus ; Danazol ; Humans ; Male ; Vietnam

Cyberlindnera fabianii (previously known as Hansenula fabianii, Pichia fabianii, and Lindnera fabianii) is a yeast species that forms a biofilm, allowing it to resist azole drugs. In this study, we report a case of fungemia with C. fabianii that was successfully treated with anidulafungin. In this case, the organism was initially misidentified as Candida utilis (with a high probability of 93%, suggesting good identification) using the VITEK 2 yeast identification card (YST ID; bio-Merieux, USA). The species responsible for the patient's fungemia was correctly identified after sequencing the internally transcribed spacer region and the D1/D2 domain of the large subunit (26S) rDNA gene. The CLSI M27-A3 broth microdilution method was used to determine the in vitro antifungal activity of anidulafungin and fluconazole against C. fabianii. The MICs of anidulafungin and fluconazole were found to be 0.03 microg/mL and 2 microg/mL, respectively. The patient recovered after 14 days of anidulafungin treatment.
Biofilms ; Candida ; Danazol ; DNA, Ribosomal ; Fluconazole ; Fungemia* ; Humans ; Pichia ; Yeasts

BACKGROUND: Because of recently increasing reports of azole-resistant Candida species, it is necessary to perform antifungal susceptibility test. E test(AB Biodisk, Sweden) is a rapid, easy-to- perform in-vitro antifungal susceptibility test. OBJECTIVE: The purpose of the study was to investigate the minimal inhibitory concentration(MIC) of azole antifungal agents against Candida sp. isolated from skin lesion using E test. METHODS: Twenty-seven clinical isolates of Candida sp.(including 24 C. albicans, 2 C. parapsilosis, and 1 C. guilliermondii) were tested. MIC endpoints of E test for itraconazole(ICZ) and fluconazole (FCZ) susceptibility were read after 24 hours for each isolates on Casitone agar. RESULTS: MIC of azole antifungal agents against Candida sp. : MIC of ICZ was 0.008-1.0microgram/mL on C. albicans, 0.023-0.125microgram/mL on C. parapsilosis, and 0.064microgram/mL on C. guilliermondii. MIC of FCZ was 0.5-4.0microgram/mL on C. albicans, 1.5-2.0microgram/mL on C. parapsilosis, and 0.5microgram/mL on C. guilliermondii. According to NCCLS(National Committee for Clinical Laboratory Standards) guidelines, two strains of C. albicans isolated from patients with Candidal intertrigo showed ICZ-resistant. CONCLUSION: We found that E test represented a simple and valuable method for susceptibility test for Candida sp.
Agar ; Antifungal Agents ; Candida* ; Danazol* ; Fluconazole ; Humans ; Intertrigo ; Skin

BACKGROUND: Nosocomial candidemia has increased over the past 2 decades. The rank order of occurrence and antifungal resistance profiles of the various species of Candida causing candidemia is important in establishing empiric treatment protocols. METHODS: We investigated antifungal susceptibilities and distribution of Candida species recovered from blood cultures over an 8-year period in Chonnam National University Hospital. The results obtained from the period 1994 through 1997 (period 1) were compared with those from the period 1998 through 2001 (period 2). Minimal inhibitory concentrations (MICs) of amphotericin B, fluconazole and itraconazole for each isolate were determined by the NCCLS broth microdilution method. RESULTS: During an 8-year period, 805 strains of Candida species were isolated from 290 patients. In period 1, the Candida species recovered most frequently from candidemic patients was C.albicans(29.5%), followed by C. parapsilosis (25.9%) and C. tropicalis (18.8%). In period 2, C. parapsilosis (31.5%) was the most common species, followed by C. albicans (23.6%), and C.glabrata (14.0%). These data, compared to those of period 1, indicate a variation in species distribution, with the proportions of C. glabrata increasing by 10.0% (P<0.005). MIC50 of amphotericin B, fluconazole and itraconazole for each species did not change appreciably during the two periods. However, resistance to fluconazole (>or=64 microgram/mL) and itraconazole (>or=1 microgram/mL) was observed more frequently in period 2 (8.0% and 20.9%, respectively) than in period 1 (2.0% and 7.0%, respectively)(P<0.05). CONCLUSIONS: These data showed that MICs of amphotericin B, fluconazole and itraconazole for each species did not change during the 8-year span, but azole resistant Candida species such as C. glabrata, increased in the latter four years (period 2).
Amphotericin B ; Candida* ; Candidemia ; Clinical Protocols ; Danazol ; Fluconazole ; Humans ; Itraconazole ; Jeollanam-do

BACKGROUND: Nosocomial candidemia has increased over the past 2 decades. The rank order of occurrence and antifungal resistance profiles of the various species of Candida causing candidemia is important in establishing empiric treatment protocols. METHODS: We investigated antifungal susceptibilities and distribution of Candida species recovered from blood cultures over an 8-year period in Chonnam National University Hospital. The results obtained from the period 1994 through 1997 (period 1) were compared with those from the period 1998 through 2001 (period 2). Minimal inhibitory concentrations (MICs) of amphotericin B, fluconazole and itraconazole for each isolate were determined by the NCCLS broth microdilution method. RESULTS: During an 8-year period, 805 strains of Candida species were isolated from 290 patients. In period 1, the Candida species recovered most frequently from candidemic patients was C.albicans(29.5%), followed by C. parapsilosis (25.9%) and C. tropicalis (18.8%). In period 2, C. parapsilosis (31.5%) was the most common species, followed by C. albicans (23.6%), and C.glabrata (14.0%). These data, compared to those of period 1, indicate a variation in species distribution, with the proportions of C. glabrata increasing by 10.0% (P<0.005). MIC50 of amphotericin B, fluconazole and itraconazole for each species did not change appreciably during the two periods. However, resistance to fluconazole (>or=64 microgram/mL) and itraconazole (>or=1 microgram/mL) was observed more frequently in period 2 (8.0% and 20.9%, respectively) than in period 1 (2.0% and 7.0%, respectively)(P<0.05). CONCLUSIONS: These data showed that MICs of amphotericin B, fluconazole and itraconazole for each species did not change during the 8-year span, but azole resistant Candida species such as C. glabrata, increased in the latter four years (period 2).
Amphotericin B ; Candida* ; Candidemia ; Clinical Protocols ; Danazol ; Fluconazole ; Humans ; Itraconazole ; Jeollanam-do